204 related articles for article (PubMed ID: 8528167)
21. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan).
Deconinck E; Cahn JY; Milpied N; Jouet JP; Vernant JP; Esperou H; Lioure B; Bordigoni P; Leblond V; Troussard X; Caillot D; Cordonnier JM; Hervé P
Bone Marrow Transplant; 1997 Nov; 20(9):731-5. PubMed ID: 9384474
[TBL] [Abstract][Full Text] [Related]
22. A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma.
Yoshihara T; Naya M; Tsunamoto K; Hojo M; Hibi S; Morimoto A; Todo S; Imashuku S
Anticancer Res; 2003; 23(2C):1739-42. PubMed ID: 12820450
[TBL] [Abstract][Full Text] [Related]
23. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
[TBL] [Abstract][Full Text] [Related]
24. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle AA; Kröger N; Zabelina T; Ayuk F; Schieder H; Renges H; Fehse N; Waschke O; Fehse B; Kabisch H; Zander AR
Bone Marrow Transplant; 2006 Jan; 37(1):45-50. PubMed ID: 16258531
[TBL] [Abstract][Full Text] [Related]
27. Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.
Ayash LJ; Ratanatharathorn V; Braun T; Silver SM; Reynolds CM; Uberti JP
Am J Hematol; 2007 Jan; 82(1):6-14. PubMed ID: 16986128
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission.
Vey N; Blaise D; Stoppa AM; Bouabdallah R; Lafage M; Sainty D; Cowen D; Viens P; Lepeu G; Blanc AP
Bone Marrow Transplant; 1994 Sep; 14(3):383-8. PubMed ID: 7994259
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
Michel G; Gluckman E; Esperou-Bourdeau H; Reiffers J; Pico JL; Bordigoni P; Thuret I; Blaise D; Bernaudin F; Jouet JP
J Clin Oncol; 1994 Jun; 12(6):1217-22. PubMed ID: 8201385
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
[TBL] [Abstract][Full Text] [Related]
31. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse.
Chiang KY; Weisdorf DJ; Davies SM; Enright H; Kersey JH; McGlave PB; Miller W; Ramsay NK; Steinbuch M; Wagner JE; Blazar BR
Bone Marrow Transplant; 1996 Jan; 17(1):39-42. PubMed ID: 8673052
[TBL] [Abstract][Full Text] [Related]
32. High-dose cytosine arabinoside and fractionated total body irradiation as a preparative regimen for the treatment of children with acute lymphoblastic leukemia and Down syndrome by allogeneic bone marrow transplantation.
Conter V; D'Angelo P; Rizzari C; Jankovic M; Dampier C; Masera G; Johnson FL
Bone Marrow Transplant; 1996 Feb; 17(2):287-9. PubMed ID: 8640182
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
35. [Allogeneic hematopoietic stem cell transplantation for acute lymphocytic leukemia].
Chen H; Ren HY; Guo NL; Huang XJ; Liu KY; Xu LP; Zhang YC; Zheng H; Wu T; Liu DH; Yang SM; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):87-90. PubMed ID: 14990046
[TBL] [Abstract][Full Text] [Related]
36. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
37. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
[TBL] [Abstract][Full Text] [Related]
38. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ
Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
40. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Przepiorka D; Ippoliti C; Giralt S; van Beisen K; Mehra R; Deisseroth AB; Andersson B; Luna M; Cork A; Lee M
Bone Marrow Transplant; 1994 Sep; 14(3):449-53. PubMed ID: 7994271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]